Group 1 - Apyx Medical is positioning itself as a leader in the surgical aesthetics market, emphasizing that surgical aesthetics provide durable and transformational results for patients [4] - The company is launching a new product, AYON, which will be a focal point of the event [3] - The market dynamics have been notably influenced by the introduction of GLP-1 drugs for weight loss, which has changed the landscape of surgical aesthetics [4] Group 2 - The event features Dr. Vanek as a key opinion leader (KOL), who will share his experiences with the AYON product [2][3] - The agenda includes an introduction by the CEO, a discussion on the commercial launch of AYON, and a Q&A session at the end [3]

Core Insights - AudioEye, Inc. focuses on digital accessibility solutions for individuals with disabilities, operating in a competitive landscape with peers like Brightcove Inc., ClearPoint Neuro, Inc., Rekor Systems, Inc., DarioHealth Corp., and Apyx Medical Corporation [1] Financial Performance - AudioEye has a Return on Invested Capital (ROIC) of -14.04%, significantly lower than its Weighted Average Cost of Capital (WACC) of 6.98%, indicating inefficiency in generating returns to cover its cost of capital [2][5] - ClearPoint Neuro, Inc. has a ROIC of -40.55% against a WACC of 7.76%, suggesting severe inefficiencies in generating returns on invested capital [3][5] - Rekor Systems, Inc. and DarioHealth Corp. report negative ROICs of -107.12% and -18.93%, respectively, with WACCs of 12.18% and 8.50%, indicating similar capital utilization challenges [4] - Apyx Medical Corporation shows a ROIC of -26.00% and a WACC of 11.51%, further emphasizing the difficulties faced by these companies in generating sufficient returns [4]

Company Overview - Apyx Medical Corporation specializes in advanced energy technology, particularly in the cosmetic surgery market with its Helium Plasma Platform Technology products marketed as Renuvion and J-Plasma [5] - Renuvion is the only FDA-cleared device for use after liposuction, addressing issues related to loose skin with more than 90 evidence-based clinical publications supporting its effectiveness [3][5] - The company aims to elevate people's lives through innovative products that provide controlled heat to tissue for desired surgical results [5] Marketing Strategy - Dolores Catania has been appointed as the Chief of Confidence for Apyx Medical's Renew You consumer marketing campaign, focusing on body contouring and the challenges of loose skin [1][2] - Catania will be featured in various marketing initiatives across multiple platforms, including social media, public relations, live engagements, and physician events [4] - The campaign emphasizes the emotional and physical benefits of Renuvion treatments, aiming to empower consumers in their personal transformations [3][4] Industry Position - Renuvion is recognized as the 1 body contouring technology trusted by doctors to effectively address loose skin challenges [3][6] - An independent survey indicated that 4 out of 5 board-certified or eligible cosmetic and plastic surgeons in the US agree on the effectiveness of Renuvion [6]

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $14.2 million, a decrease of 3% compared to $14.7 million in Q4 2023 [7][23] - Gross profit for Q4 2024 increased to $9 million, with a gross profit margin of 63.0%, up from 60.9% in the prior year [25] - Net loss attributable to stockholders was $4.6 million or $0.12 per share for Q4 2024, compared to a net loss of $9.6 million or $0.28 per share in Q4 2023 [28] Business Segment Data and Key Metrics Changes - Advanced Energy segment revenue was flat at approximately $12.1 million, with a 30% increase compared to Q3 2024 [8][24] - OEM segment sales decreased by 16% to approximately $1.6 million in Q4 2024 compared to Q4 2023 [24] - Domestic revenue increased by 1% year-over-year to $10.6 million, while international revenue decreased by 8% to $3.7 million [25] Market Data and Key Metrics Changes - The aesthetic market has faced challenges due to the macroeconomic environment and the adoption of GLP-1 drugs, which have diverted discretionary spending [9][10] - The company believes that patients who have lost weight due to GLP-1 drugs will seek surgical solutions, positioning the Renuvion system favorably [11][12] Company Strategy and Development Direction - The company is focusing on the launch of the AYON Body Contouring System, expected in the second half of 2025, which integrates multiple surgical technologies [16][18] - Apyx Medical aims to capitalize on the growing demand for surgical aesthetics, particularly for patients experiencing skin laxity after significant weight loss [12][60] - A restructuring program was implemented to reduce U.S. workforce by nearly 25%, aiming for annualized cost savings of approximately $4.3 million [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the momentum in the Advanced Energy segment and the potential for growth in 2025 [8][9] - The company anticipates total revenue for 2025 to be in the range of $47.6 million to $49.0 million, reflecting a slight increase from 2024 [30] - Management noted that the aesthetic space is experiencing disruption due to the impact of GLP-1 drugs, which could benefit companies with the right technologies [62] Other Important Information - The company completed a registered direct offering with net proceeds of approximately $6.8 million to strengthen its balance sheet [21] - Cash and cash equivalents as of December 31, 2024, were $31.7 million, down from $43.7 million a year earlier [29] Q&A Session Summary Question: Confirmation of gross margin for 2025 - Management confirmed that they expect gross margins to be around 60% for 2025 [34][35] Question: Timing and revenue expectations for AYON - Management indicated that the guidance for AYON has not been updated despite the earlier submission for FDA approval, and revenue expectations remain conservative [40][41] Question: Changes in direct-to-consumer campaign and future outlook - Management highlighted the success of the DTC campaign and the importance of addressing the needs of patients experiencing skin laxity due to weight loss [50][52] Question: Domestic vs. international market performance - Management noted that the U.S. market is performing better due to early adoption of GLP-1 drugs, with expectations for similar trends internationally [56][58] Question: Adoption of GLP-1s and utilization of Renuvion - Management reported growth in handpiece sales in the U.S. and noted that surgical practices are adapting to treat patients with skin laxity effectively [66][70] Question: Upgrades for the Apyx One Console - Management stated that there is still a significant number of customers who need to upgrade to the Apyx One Console before AYON's launch [72][75]